Whalesbook
Valuation ka pressure badh raha hai!
Jubilant Ingrevia ne Q4FY26 mein ₹11.8 billion ka revenue report kiya, jo analysts ke expectation ke hisab se tha. Lekin stock, jo abhi ₹697 ke aas paas trade kar raha hai, uska P/E ratio 44x hai. Bahut se analysts ko yeh valuation justify karna mushkil lag raha hai. Unka kehna hai ki company ki earnings growth ki jo outlook hai aur global competition ki jo reality hai, uske beech ka difference badh raha hai. Pehle toh market ko stock ka higher-margin products ki taraf shift pasand aa raha tha, but ab 'Reduce' rating se lagta hai ki investors chemical industry ke structural risks ko bhi consider kar rahe hain.
Competition aur tezi se badh rahi hai!
Specialty chemicals sector mein recovery tough ho gayi hai kyuki Chinese manufacturers aggressive pricing kar rahe hain. Jubilant Ingrevia ne apna CDMO pipeline advance kiya hai, jisme ek agrochemical contract bhi hai. Lekin ye gains Pyridine aur Picoline jaise core areas mein downturn ki wajah se compensate ho rahe hain. Dusri companies ne toh integration ya strong market position se margins ko stable rakha hai, par Jubilant ka dependency commodity-linked intermediates par hai, jisse profits external price fluctuations se bahut sensitive hain. Pharma clients se demand bhi kam hai, jisse value creation ki jagah price-based competition chal rahi hai.
Risks kya hain?
Risk ki baat karein toh, kuch concerns hain. Management ne future expansion ke liye ₹20 billion ka capex kiya hai. Lekin execution ek bada risk hai. Agar naye Vitamin B3 facility mein production mein delay hua ya high-value CDMO products ke liye regulatory standards meet nahi hue, toh profitability par serious impact ho sakta hai. Waise toh debt-to-EBITDA ratio manageble hai (1.2x-1.3x), par agar chemical intermediates mein margin pressure next fiscal year mein bhi chalta raha, toh yeh bhi strain ho sakta hai. Investors ko stock ki historical volatility par bhi dhyan dena chahiye, jo raw material costs jaise acetic acid ke liye sensitive hai.
Aage ka kya plan hai?
Analysts ki company ke long-term growth potential par alag-alag views hain. FY28 ke liye CDMO business ko main driver mana ja raha hai. Lekin higher valuations ke liye Jubilant Ingrevia ko price-sensitive, generic products se upar uth kar value chain mein climb karna hoga. Brokerages naye capex ke utilization rates ko closely monitor kar rahe hain, jo stock re-rating ka ek important indicator ho sakta hai.